IntegraGen: 2026 Half-Year Results Marked by Losses and Legal Proceedings

On October 29, 2026, IntegraGen published its estimated results for the first half of the year, marked by significant financial losses. The company reported revenues of €2.0 million, a 23% decrease compared to the previous year, while operating expenses decreased by 15%. Consequently, the net loss amounted to €1.1 million.

Having entered receivership proceedings on June 15, 2026, IntegraGen saw its cash position decrease to €0.2 million as of June 30. The continuation of operations is uncertain, depending on the outcome of the Paris Court of Appeal's appeal regarding the transfer plan and the liquidation proceedings.

CEO Bérengère Génin emphasizes the teams' commitment despite these challenges. The continuation of operations remains uncertain, while the company's shareholders face significant financial risks.